These findings confirm the robustness, accuracy, and efficiency of the Xpert® BCR-ABL Ultra assay, supporting its use as a reliable alternative to currently validated systems for the routine clinical monitoring of CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.